NASDAQ
Liminatus Pharma, Inc. Class A Common Stock (LIMN) has a price/fcf ratio of -1.45x as of Monday, May 25, 2026. This represents a 98.41% increase compared to its 12-month average of -91.06x. The price-to-free-cash-flow ratio measures a stock's price relative to its free cash flow per share, reflecting how efficiently a company generates cash.
No price data available for this timeframe.